Context Therapeutics financials
$0.3190−2.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.38 | $-0.46 | $-1.50 | $-0.93 | $-3.69 |
| EBITDA | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Operating cash flow | -$26.4M | -$14.6M | -$21.0M | -$14.0M | -$9.0M |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$14.1M | — |
| Diluted shares | 95.2M | 58.4M | 16.0M | 16.0M | 2.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $66.0M | $94.4M | $14.4M | $35.5M | $49.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M |
| Shareholders' equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology